Antibiotics have been one of the most transformational discoveries in medicine saving millions of lives around the world. The rise of resistance poses an unprecedented threat to public health rekindling a drive for new, effective and safe drugs to beat the
superbugs, combined with efforts to raise awareness around the use of antimicrobials.
This conference takes a holistic look at the issues and aims to equip delegates to take on the challenges of conserving the effectiveness of existing antibacterial drugs, developing new ones and tackling biosecuiry and Ebola threats. Bringing in voices from pharma, academia, government, regulatory perspectives, consultants and funding bodies this conference is the ideal meeting place to share the latest updates, case studies and strategies to seize the opportunities ahead and usher in the next generation of
superdrugs.
Benefits of Attending
- Receive the latest updates and case studies on preclinical and clinical developments
- Scan horizons on anti-microbial resistance and understand initiatives to control antimicrobial use
- Look at alternative approaches including phage and peptide and approaches
- Explore the latest updates in funding and reimbursement
- Review the current status of antimicrobial resistance and the threats and targets landscape
- Understand the potential of rapid point of care diagnostics
Plus Two Interactive Half-Day Pre-Conference Workshops | Tuesday 24th March
A:
A Vision for the Future; Designing Antimicrobials to Meet Future NeedsWorkshop Leader: Dr Keith Williams, Director and Consultant, KW Drug Developments Ltd & Boyd Consultants
8.30am – 12.30pm
B:
Technical Aspects of Licensing an AntibioticWorkshop Leader: David Scott, Consultant, PharmaConsulting
1.30pm – 4.30pm
Speakers
- Colin J Suckling, Research Professor of Chemistry, University of Strathclyde
- David Findlay, Global Product Strategy, GlaxoSmithkline
- David Scott, Licensing & Business Development Consultant, PharmaConsulting
- David Spring, Professor of Chemistry, Cambridge University
- David Williams, Chief Executive Officer, Discuva
- Dawn Firmin, Head of Project Management, MGB Biopharma
- Domingo Gargallo-Viola, Chief Scientific Officer, ABAC Therapeutics
- Fiona Marston, Chief Executive, Absynth Biologics
- Frederick Wittke, Medical Director, Debiopharm International
- Ian Friedland, Chief Medical Officer, Achaogen, Inc.
- Jerome Gabard, CEO, Pherecydes
- Jorge Mestre-Ferrandiz, Director of Consulting, Office of Health Economics (OHE)
- Line Matthiessen, Head of Infectious Diseases and Public Health Unit, European Commision
- Melissa Stundick, Acting Branch Chief, Broad Spectrum Antimicrobials Program, BARDA
- Neil Stokes, Head of Biology, Redx Anti-Infectives
- Richard Bax, Senior Partner, TranScrip Partners
- Richard Bergstrom, Director General, EFPIA
- Ryan Cirz, Director of Biology, Achaogen
- Shiva Dustdar, Head of RDI Advisory, European Investment Bank
- Timothy Jinks, Senior Business Analyst, Wellcome Trust Innovations
- William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Venue
Holiday Inn Regents ParkCarburton Street
London
W1W 5EE England
